CKD Bio Corp. (063160.KS)
KRW 22500.0
(-1.96%)
KRW 22500.0
(-1.96%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 25.19 Billion KRW | -20.27% |
| 2022 | 31.6 Billion KRW | 27.74% |
| 2021 | 24.73 Billion KRW | 22.12% |
| 2020 | 20.25 Billion KRW | -2.43% |
| 2019 | 20.76 Billion KRW | 26.51% |
| 2018 | 16.41 Billion KRW | 3.52% |
| 2017 | 15.85 Billion KRW | 7.32% |
| 2016 | 14.77 Billion KRW | 18.42% |
| 2015 | 12.47 Billion KRW | 6.36% |
| 2014 | 11.72 Billion KRW | -8.03% |
| 2013 | 12.75 Billion KRW | -9.62% |
| 2012 | 14.11 Billion KRW | 43.83% |
| 2011 | 9.81 Billion KRW | -26.68% |
| 2010 | 13.38 Billion KRW | 8.72% |
| 2009 | 12.3 Billion KRW | -10.6% |
| 2008 | 13.76 Billion KRW | 48.35% |
| 2007 | 9.28 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 42.34 Billion KRW | 730.38% |
| 2024 Q2 | 45.93 Billion KRW | 8.46% |
| 2024 Q3 | 41.3 Billion KRW | -86.06% |
| 2023 Q2 | 7.39 Billion KRW | 9.99% |
| 2023 Q4 | 5.09 Billion KRW | 162.15% |
| 2023 FY | 25.19 Billion KRW | -20.27% |
| 2023 Q1 | 6.72 Billion KRW | -30.49% |
| 2023 Q3 | -8.2 Billion KRW | -210.92% |
| 2022 Q3 | 7.5 Billion KRW | 2.24% |
| 2022 Q2 | 7.34 Billion KRW | 3.72% |
| 2022 Q1 | 7.07 Billion KRW | 6.6% |
| 2022 FY | 31.6 Billion KRW | 27.74% |
| 2022 Q4 | 9.67 Billion KRW | 28.94% |
| 2021 Q2 | 5.99 Billion KRW | 0.05% |
| 2021 Q1 | 5.98 Billion KRW | 8.51% |
| 2021 Q3 | 6.12 Billion KRW | 2.18% |
| 2021 Q4 | 6.63 Billion KRW | 8.46% |
| 2021 FY | 24.73 Billion KRW | 22.12% |
| 2020 Q1 | 4.4 Billion KRW | -19.55% |
| 2020 Q3 | 5.15 Billion KRW | -0.45% |
| 2020 Q4 | 5.51 Billion KRW | 7.05% |
| 2020 FY | 20.25 Billion KRW | -2.43% |
| 2020 Q2 | 5.17 Billion KRW | 17.46% |
| 2019 Q1 | 4.72 Billion KRW | 3.8% |
| 2019 Q3 | 5.53 Billion KRW | 10.14% |
| 2019 Q4 | 5.47 Billion KRW | -1.02% |
| 2019 FY | 20.76 Billion KRW | 26.51% |
| 2019 Q2 | 5.02 Billion KRW | 6.43% |
| 2018 Q2 | 3.48 Billion KRW | -17.96% |
| 2018 Q3 | 4.12 Billion KRW | 18.24% |
| 2018 FY | 16.41 Billion KRW | 3.52% |
| 2018 Q1 | 4.25 Billion KRW | 7.68% |
| 2018 Q4 | 4.54 Billion KRW | 10.32% |
| 2017 Q1 | 3.83 Billion KRW | -6.66% |
| 2017 FY | 15.85 Billion KRW | 7.32% |
| 2017 Q4 | 3.94 Billion KRW | -3.3% |
| 2017 Q3 | 4.08 Billion KRW | 2.39% |
| 2017 Q2 | 3.98 Billion KRW | 3.92% |
| 2016 FY | 14.77 Billion KRW | 18.42% |
| 2016 Q4 | 4.11 Billion KRW | 19.0% |
| 2016 Q3 | 3.45 Billion KRW | -6.56% |
| 2016 Q2 | 3.69 Billion KRW | 5.26% |
| 2016 Q1 | 3.51 Billion KRW | 4.29% |
| 2015 FY | 12.47 Billion KRW | 6.36% |
| 2015 Q2 | 2.89 Billion KRW | -1.11% |
| 2015 Q3 | 3.28 Billion KRW | 13.71% |
| 2015 Q1 | 2.92 Billion KRW | 2.02% |
| 2015 Q4 | 3.36 Billion KRW | 2.37% |
| 2014 Q3 | 3.19 Billion KRW | 14.92% |
| 2014 Q2 | 2.77 Billion KRW | -3.87% |
| 2014 Q1 | 2.89 Billion KRW | -0.35% |
| 2014 Q4 | 2.86 Billion KRW | -10.19% |
| 2014 FY | 11.72 Billion KRW | -8.03% |
| 2013 FY | 12.75 Billion KRW | -9.62% |
| 2013 Q2 | 3.66 Billion KRW | 10.34% |
| 2013 Q3 | 2.85 Billion KRW | -22.16% |
| 2013 Q1 | 3.32 Billion KRW | -26.89% |
| 2013 Q4 | 2.9 Billion KRW | 1.53% |
| 2012 FY | 14.11 Billion KRW | 43.83% |
| 2012 Q4 | 4.54 Billion KRW | 36.66% |
| 2012 Q3 | 3.32 Billion KRW | 1.55% |
| 2012 Q2 | 3.27 Billion KRW | 10.96% |
| 2012 Q1 | 2.95 Billion KRW | 475.7% |
| 2011 Q1 | 3.51 Billion KRW | -1.27% |
| 2011 FY | 9.81 Billion KRW | -26.68% |
| 2011 Q4 | 513.16 Million KRW | -85.53% |
| 2011 Q3 | 3.54 Billion KRW | 58.55% |
| 2011 Q2 | 2.23 Billion KRW | -36.38% |
| 2010 Q3 | 3.19 Billion KRW | -12.8% |
| 2010 FY | 13.38 Billion KRW | 8.72% |
| 2010 Q2 | 3.66 Billion KRW | 13.22% |
| 2010 Q1 | 3.23 Billion KRW | 4.3% |
| 2010 Q4 | 3.56 Billion KRW | 11.4% |
| 2009 Q4 | 3.1 Billion KRW | 5.89% |
| 2009 FY | 12.3 Billion KRW | -10.6% |
| 2009 Q2 | 3.45 Billion KRW | 7.27% |
| 2009 Q1 | 3.22 Billion KRW | -30.39% |
| 2009 Q3 | 2.93 Billion KRW | -15.17% |
| 2008 Q3 | 4.38 Billion KRW | 82.52% |
| 2008 Q4 | 4.62 Billion KRW | 5.57% |
| 2008 Q1 | 2.35 Billion KRW | -12.72% |
| 2008 FY | 13.76 Billion KRW | 48.35% |
| 2008 Q2 | 2.4 Billion KRW | 1.94% |
| 2007 FY | 9.28 Billion KRW | 0.0% |
| 2007 Q3 | 2.12 Billion KRW | 0.69% |
| 2007 Q1 | 2.35 Billion KRW | 0.0% |
| 2007 Q2 | 2.11 Billion KRW | -10.16% |
| 2007 Q4 | 2.69 Billion KRW | 26.91% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 47.25 Billion KRW | 46.68% |
| Dong-A Socio Holdings Co., Ltd. | 297.99 Billion KRW | 91.545% |
| Ildong Holdings Co., Ltd. | 278.43 Billion KRW | 90.951% |
| HANDOK Inc. | 153.76 Billion KRW | 83.614% |
| Kukje Pharma Co., Ltd. | 69.21 Billion KRW | 63.597% |
| Yuhan Corporation | 489.94 Billion KRW | 94.857% |
| Dong-A ST Co., Ltd. | 306.95 Billion KRW | 91.792% |
| SAMSUNG PHARM. Co., LTD. | 41.78 Billion KRW | 39.708% |
| Hanmi Pharm. Co., Ltd. | 610.97 Billion KRW | 95.876% |
| Hanall Biopharma Co.,Ltd | 71.98 Billion KRW | 64.998% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | 85.532% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.05 Billion KRW | 37.094% |
| MYUNGMOON Pharm co.,Ltd | 93.55 Billion KRW | 73.068% |
| Hana Pharm Co., Ltd. | 114.72 Billion KRW | 78.038% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | 46.68% |
| Ilsung Pharmaceuticals Co., Ltd. | 42.47 Billion KRW | 40.676% |
| REYON Pharmaceutical Co., Ltd. | 75.04 Billion KRW | 66.428% |
| Aprogen pharmaceuticals,Inc. | 58.64 Billion KRW | 57.036% |
| JW Holdings Corporation | 301.25 Billion KRW | 91.636% |
| Ildong Pharmaceutical Co., Ltd. | 260.95 Billion KRW | 90.345% |
| Chong Kun Dang Pharmaceutical Corp. | 408.65 Billion KRW | 93.834% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 89.454% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | 80.265% |
| Hyundai Pharmaceutical Co., Ltd. | 68.31 Billion KRW | 63.116% |
| Samil Pharmaceutical Co.,Ltd | 65.75 Billion KRW | 61.68% |
| Jeil Pharmaceutical Co.,Ltd | 174.92 Billion KRW | 85.596% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | 46.68% |
| Kwang Dong Pharmaceutical Co., Ltd. | 249.12 Billion KRW | 89.886% |
| Daewoong pharmaceutical Co.,Ltd | 560.43 Billion KRW | 95.504% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 89.454% |
| Yuhan Corporation | 489.94 Billion KRW | 94.857% |
| Jeil Pharma Holdings Inc | 193.66 Billion KRW | 86.99% |
| Yungjin Pharm. Co., Ltd. | 69.46 Billion KRW | 63.731% |
| Suheung Co., Ltd. | 56.03 Billion KRW | 55.033% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 89.454% |
| Samjin Pharmaceuticals Co., Ltd. | 126.39 Billion KRW | 80.066% |
| Korea United Pharm Inc. | 118.21 Billion KRW | 78.686% |
| Daewon Pharmaceutical Co., Ltd. | 221.99 Billion KRW | 88.651% |
| Dongwha Pharm.Co.,Ltd | 165.11 Billion KRW | 84.74% |
| Whan In Pharm Co.,Ltd. | 66.41 Billion KRW | 62.065% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | 80.265% |
| Chong Kun Dang Holdings Corp. | 350.71 Billion KRW | 92.816% |
| Boryung Corporation | 285.16 Billion KRW | 91.164% |
| Bukwang Pharmaceutical Co., Ltd. | 87.54 Billion KRW | 71.219% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | 85.532% |
| JW Lifescience Corporation | 20.26 Billion KRW | -24.352% |